Extended indication Smouldering multipel myeloom.
Therapeutic value No estimate possible yet
Total cost 13,375,943.00
Registration phase Clinical trials

Product

Active substance Daratumumab
Domain Oncology and Hematology
Reason of inclusion Indication extension IND
Main indication Multiple Myeloma
Extended indication Smouldering multipel myeloom.
Proprietary name Darzalex
Manufacturer Janssen
Mechanism of action Other, see general comments
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Unknown
Particularity Unknown
ATMP Unknown
Submission date May 2022
Expected Registration March 2023
Orphan drug Yes
Registration phase Clinical trials
Additional remarks Fabrikant verwacht registratie in het maart 2023

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Dosage per administration 1800mg
References NCT03301220.
Additional remarks Jaar 1: 23 toedieningen; jaar 2 en 3: 13 toedieningen. Maximale behandelduur van 36 maanden.

Expected patient volume per year

Patient volume < 133

Market share is generally not included unless otherwise stated.

References NKR, Pakketadvies daratumumab.
Additional remarks Jaarlijks aantal nieuwe multipel myeloma patiënten bedraagt 1.333 (NKR 2018), waarvan 10% asymptomatisch: 133.

Expected cost per patient per year

Cost < 100,571.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

References Fabrikant, G-standaard
Additional remarks Jaar 1: €100.571; Jaar 2 en 3: €56.845. Op basis van de lijstprijs.

Potential total cost per year

Total cost 13,375,943.00

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information